The clinicopathological and prognostic value of HSP27 in hepatocellular carcinoma: a systematic review and meta-analysis

Figures & data

Table 1 Characteristics of studies included in the meta-analysis

Authors	Year	Country	Kind	No. of patients	Antibody company	Antibody concentration	Expression cancer (+/−), control (+/−)	Age >60 (+/−), <60 (+/−)	AFP positive (+/−), negative (+/−)	HBsAg yes (+^/−), no (+/−)	Tumor size #5 cm (+/−), >5 (+/−)	Metastasis, metastasis (+/−), Non-metastasis (+/−)	Vascular invasion yes (+^/−), no (+/−)	Differentiation low (+/−), high, and moderate (+/−)	UICC stage I, II (+/−), III, IV (+/−)	Survival information	Quality score
Shen et al^Citation20	2013	China	HCC	32	Fujian Maixin Technology	NA	18/14	10/12	10/4	10/8	6/8	NA	NA	12/0	6/12	NA	6
							3/32	8/2	8/20	8/6	12/6			6/14	12/2
Guo^Citation21	2012	China	HCC	68	Fujian Maixin Technology	1:200	51/17	NA	NA	44/9	26/7	15/4	NA	23/2	NA	NA	6
							42/26			7/8	25/10	29/20		28/15
Dai et al^Citation22	2009	China	HCC	45	NeoMarkers	NA	30/15	21/12	NA	NA	18/10	22/4	24/6	II/I	NA	NA	6
							0/35	9/3			12/5	8/11	6/9	19/14
Liang et al^Citation15	2011	China	HCC	34	NA	NA	20/14	NA	NA	NA	6/5	15/4	12/1	15/5	NA	NA	6
							10/24				14/9	5/10	9/13	5/9
Daimei et al^Citation16	2016	Japan	HCC	194	Streegen	1:400	118/76	97/53	NA	20/11	NA	28/51	71/41	20/10	42/34	NA	8
							NA	21/23		98/65		40/74	47/35	98/66	76/42
Mee et al^Citation24	2005	Korea	HCC	71	NeoMarkers	1:50	44/27	NA	NA	40/13	16/8	12/10	16/12	36/15	12/9	NA	8
							NA			4/14	28/19	32/17	28/15	8/12	32/18
John et al^Citation23	2006	China	HCC	67	Santa cruz	1:500	51/16	43/14	22/1	44/14	NA	NA	33/8	NA	34/8	NA	8
							NA	8/2	29/15	7/2			18/8		17/8
King et al^Citation17	2000	China	HCC	58	Novocastra Laboratories, Ltd	1:100	28/30	NA	18/14	NA	16/12	NA	20/16	17/5	NA	OS DFS	7
							5/53		12/14		12/18		8/14	11/25
Harimoto et al^Citation18	2004	Japan	HCC	60	Novocastra Laboratories, Ltd	1:200	26/34	19/27	NA	10/20	NA	6/6	9/14	8/13	NA	OS DFS	8
							NA	7/7		16/14		20/28	17/20	18/21
Zhang et al^Citation19	2016	China	HCC	167	Cell sigaling Technology	1:1,000	81/86	NA	NA	NA	NA	NA	NA	NA	NA	Os DFs	9
Hung et al^Citation25	2017	China	HCC	80	Abcam	1:750	NA	53/8	NA	NA	NA	NA	NA	19/0	39/8	OS	8
								15/4						49/12	29/4

Note: + means over-expressed and - means lower-expressed.

Abbreviations: AFP, α-fetoprotein; DFS, disease-free survival; HBsAg, hepatitis B virus surface antigen; HCC, hepatocellular carcinoma; OS, overall survival; UICC, Union for International Cancer Control; NA, not applicable.

Figure 1 Flowchart of study selection process.

Table 2 HSP27 clinicopathological features for HCC

Heterogeneity
Clinicopathological features	No. of studies	No. of patients	Pooled OR (95% CI)	PHet	I^2 (%)	P-value	Model used
Expression	5	237	7.00 (2.35–20.79)	0.002	76.6	0.000	Random
Gender	6	478	1.13 (0.72–1.77)	0.142	39.5	0.606	Fixed
AFP	3	167	3.86 (1.11–13.39)	0.113	54.2	0.034	Random
HBsAg	6	492	1.72 (0.65–4.52)	0.001	74.8	0.275	Random
Tumor size	6	304	1.19 (0.74–1.92)	0.535	0.0	0.479	Fixed
Metastasis	6	471	1.96 (0.91–4.24)	0.013	65.2	0.086	Random
Vascular invasion	7	530	1.71 (0.93–3.15)	0.037	55.2	0.083	Random
Differentiation	9	642	3.81 (1.79–8.08)	0.012	59.0	0.000	Random
TNM stage	5	444	0.68 (0.33–1.38)	0.068	54.2	0.282	Random

Abbreviations: AFP, α-fetoprotein; Fixed, fixed-effects model; HCC, hepatocellular carcinoma; OR, odds ratio; Random, random-effects model.

Figure 2 Forest plot and funnel plots of studies evaluating the relationship between HSP27 expression and clinicopathological features.

Notes: (A) Expression; (B) gender; (C) AFP level. Weights are from random effects analysis.
Abbreviations: AFP, α-fetoprotein; OR, odds ratio.

Figure 3 Forest plot and funnel plots of studies evaluating the relationship between HSP27 expression and clinicopathological features.

Notes: (A) HBsAg; (B) tumor size; (C) metastasis. Weights are from random effects analysis.
Abbreviation: OR, odds ratio.

Figure 4 Forest plot and funnel plots of studies evaluating the relationship between HSP27 expression and clinicopathological features.

Notes: (A) Vascular invasion; (B) tumor differentiation; (C) TNM stage. Weights are from random effects analysis.
Abbreviation: OR, odds ratio.

Figure 5 Forest plot and funnel plots of studies evaluating the relationship between HSP27 expression and prognosis of HCC patients.

Notes: (A) Overall survival; (B) disease-free survival. Weights are from random effects analysis.
Abbreviations: HCC, hepatocellular carcinoma; HR, hazard ratio.

ShenDLiLiJianG热休克蛋白-27 与磷脂酰肌醇蛋白聚糖-3 在原 发性肝癌中的表达及意义 [Expression of HSP27 and GPC-3 in primary hepatic cancer and its clinical implication]Chongqing Med J201314593598 Chinese

 Google Scholar

GuoWExpression of HSP27 and VEGF in HCC and its Clinical Implication. [master’s thesis]Guilin Medical University of China2012

 Google Scholar

DaiFJMaoHuiFWeiXHSP27在肝癌中的表达及临床意义 [Expression of HSP27 in hepatocellular carcinoma (HCC) and its clinical implication]Chin Cancer Clin20092578581 Chinese

 Google Scholar

LiangDQXiaopingLLinglingZXinghuoT肝癌组织中Cyr61、VEGF 和HSP27的表达和临床意义 [Expression and their clinical significance of Cyr61, VEGF and HSP27 in hepatocellular carcinoma]Shandong Med J2011511921 Chinese

 Google Scholar

DaimeiEtoHisakaTHoriuchiHExpression of HSP27 in Hepatocellular CarcinomaAnticancer Res20163673775377927354654

 PubMed Web of Science ®Google Scholar

MeeJOOChiJGLeeHExpressions of HSP70 and HSP27 in hepatocellular carcinomaJ Korean Med Sci200520582983416224158

 PubMed Web of Science ®Google Scholar

LukJMLamCTSiuAFProteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic valuesProteomics2006631049105716400691

 PubMed Web of Science ®Google Scholar

KingKLLiAFChauGYPrognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survivalCancer200088112464247010861421

 PubMed Web of Science ®Google Scholar

HarimotoNShimadaMAishimaSThe role of heat shock protein 27 expression in hepatocellular carcinoma in Japan: special reference to the difference between hepatitis B and CLiver Int200424431632115287854

 PubMed Web of Science ®Google Scholar

ZhangYTaoXJinGA targetable molecular chaperone Hsp27 confers aggressiveness in hepatocellular carcinomaTheranostics20166455857026941848

 PubMed Web of Science ®Google Scholar

HungCSHuangCYLeeCHIGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasisOncotarget2017833549785499228903396

 PubMedGoogle Scholar